PrimeGenX Therapeutics Co., Ltd.

北京普祺医药科技股份有限公司

Develops small-molecule drugs for immune-inflammation diseases, delivered locally via gels, sprays, tablets and ophthalmic solutions. Lead candidate is a JAK1/2 inhibitor for atopic dermatitis and allergic rhinitis, alongside three innovative and five generic drug candidates in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Connected or related major customers / suppliers
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Investments and fair-value assets
• Non-recurring gains and losses
• Chapter 18A biotech